Recombinant Human Tumor Necrosis Factor Ligand/TNFSF13/APRIL (N-Flag-His)
|Amount :||50 µg|
|Content :||Lyophilized from a 0.2 µm filtered solution of PBS, pH7.4.|
|AA sequence :||Recombinant Human A proliferation-inducing ligand is produced by our Mammalian expression system and the target gene encoding Lys112-Leu250 is expressed with a Flag-His tag at the C-terminus.|
|Alternative Name :||Tumor necrosis factor ligand superfamily member 13; A proliferation-inducing ligand; APRIL; TNF- and APOL-related leukocyte expressed ligand 2; TALL-2; TNF-related death ligand 1; TRDL-1; CD256; TNFSF13|
APRIL(a proliferation-inducing ligand), also known as TNFSF13, TALL2, TRDL1, and CD256, is a member of the TNF ligand superfamily. It is synthesized as a 32 kDa proprotein which is cleaved by furin in the Golgi to release the active 17 kDa soluble molecule. Secreted human APRIL, which consists almost entirely of a single TNF homology domain, shares 85% amino acid sequence identity with mouse and rat APRIL. Both APRIL and its close relative BAFF bind and signal through the TNF superfamily receptors TACI and BCMA, while BAFF additionally functions through BAFF R. APRIL binds to heparan sulfate proteoglycans (HSPGs) independently of its binding to TACI and BCMA. APRIL can form bioactive heterotrimers with BAFF, and these circulate in the serum of patients with rheumatic immune disorders. APRIL enhances the proliferation and survival of plasma cells and also promotes T cell-dependent humoral responses. APRIL levels are elevated in the serum during coronary artery disease, and it is also elevated in many cancers primarily due to expression by tumor-infiltrating neutrophils.